This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

5 Earnings Stocks Poised to Pop

BioMarin Pharmaceutical

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

My first earnings short-squeeze trade idea is biotech player BioMarin Pharmaceutical (BMRN), which is set to report its numbers on Thursday after the market close. This company develops and commercializes pharmaceuticals for serious diseases and medical conditions. Wall Street analysts, on average, expect BioMarin Pharmaceutical to report revenue of $115.30 million on a loss of 11 cents per share.

If you're looking for a technically strong stock that's within range of hitting a new 52-week high post-earnings, then make sure to take a hard look at shares of BioMarin Pharmaceutical. This stock is currently trading just one point off its 52-week high of $38.95 as we head closer to its quarterly earnings report.

The current short interest as a percentage of the float for BioMarin Pharmaceutical is notable at 7%. That means that out of the 113.76 million shares in the tradable float, 7.93 million shares are sold short by the bears.

>>6 Drug Stocks Unworthy of a Biotech Bull Market

From a technical perspective, BMRN is currently trading above both its 50-day and 200-day moving averages, which is bullish. This stock has been uptrending strong for months, with shares consistently making higher lows and higher highs, which is bullish price action. Now this stock is within range of triggering a big post-earnings breakout, and the upside volume patterns during the past few weeks have been ridiculously strong.

If you're bullish on BMRN, I would look for long-biased trades following its report if the stock takes out $38.95 to $40 a share with strong volume. Look for volume that's tracking in close to or above its three-month average of 991,058 shares. If those levels get taken out with volume, it would be very bullish since it will push BMRN into all-time high territory. I would look for a large spike of 10% or more post-earnings if that breakout gets triggered.

I would avoid BMRN or look for short-biased trades after they report if the stock fails to trigger that breakout and then drops below some near-term support at $37 a share with volume. I would target a drop back towards its 50-day moving average of $35.26 a share, or possibly lower if the bears slam this down post-earnings.

2 of 6

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,156.85 +24.88 0.15%
S&P 500 2,001.57 +2.59 0.13%
NASDAQ 4,562.1890 +9.43 0.21%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs